Holen Sie sich die Stockscreener-App
42.13
8.83%
3.42
Handel nachbörslich:
42.24
0.11
+0.26%
Viking Therapeutics Inc Aktie (VKTX) Neueste Nachrichten
CRISPR Therapeutics vs. Viking Therapeutics: Is a Gene-Editing or Weight Loss Focused Stock Is a Better Buy in 2026? - The Motley Fool
Piper Sandler reiterates Overweight on Viking Therapeutic stock - Investing.com
How Much Could $1,000 Invested in Viking Therapeutics Be Worth by 2030? - AOL.com
Viking Therapeutics (VKTX) Starts VK3019 Trial As Obesity Pipeline Narrative Meets Valuation - simplywall.st
Viking Therapeutics (NASDAQ: VKTX) Faces Uphill Battle In $150 Billion GLP-1 Race Toward 2030 - foreignpolicyjournal.com
OABI,VKTX Revenue Breakdown - Finviz
CRISPR Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
CRISPR Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Could This Healthcare Stock Help You Build a Real Fortune Over the Next 20 Years? - Yahoo Finance
VKTX Stock Rallies After Hours On Optimism Around Company’s Obesity Pipeline - Stocktwits
VKTX Stock Has Nearly 300% Wall Street Upside — Is Viking’s Oral Obesity Pill The Next Novo Nordisk-Style Breakout? - Stocktwits
VKTX Stock Outpaces LLY, ALT Ahead Of Earnings – Retail Eyes Breakout Ahead - Stocktwits
Quick ratio of Viking Therapeutics, Inc. – XETR:1VT - TradingView
Is Viking Therapeutics Stock Going to $50? Here's What the Bulls and Bears Are Saying - The Motley Fool
VKTXViking Therapeutics Inc Options - Finviz
VKTX Stock Extends Red-Hot Streak: Insider Scoops Up Shares As Multiple Phase 3 Trials Loom This Year In Obesity Race - Stocktwits
Viking Therapeutics Moves Closer To Challenging Ozempic With Phase 3 Trial Progress - Stocktwits
Here's Why Viking Therapeutics Stock Surged Higher in June - The Motley Fool
VKTX News | VIKING THERAPEUTICS INC (NASDAQ:VKTX) - ChartMill
Viking Therapeutics, Inc. (VKTX) sees a more significant dip than broader market: Some facts to know - MSN
Viking Therapeutics, Inc. (VKTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know - Yahoo Finance
Is Viking Therapeutics Stock Going to $100? - The Motley Fool
Viking Therapeutics, Inc. (VKTX) Latest Stock News & Headlines - Yahoo Finance
Why Viking Therapeutics (VKTX) Is Up 22.2% After Advancing VK3019 Into First-in-Human Obesity Trial - Sahm
Cantor Fitzgerald reiterates Viking Therapeutic stock rating at Overweight - Investing.com
Cantor Fitzgerald reiterates Viking Therapeutic stock rating at Overweight By Investing.com - Investing.com Canada
Viking Therapeutics holds at $5B valuation amid GLP-1 drug competition and awaits oral study results. - Pluang
VKTX Stock Clocks Best Day In Nearly 3 Months On Obesity Pipeline Optimism, Buyout Speculation - Stocktwits
Viking Therapeutics: Updating Pipeline Potential As Oral GLP‑1s Accelerate (NASDAQ:VKTX) - Seeking Alpha
Can Eli Lilly's New Drugs Fuel Growth Beyond Its GLP-1 Blockbusters? - TradingView
VKTX.O - Reuters
Is Viking Therapeutics stock a no-brainer buy below $35? - MSN
Is it worth investing in Viking Therapeutics (VKTX) based on Wall Street's bullish views? - MSN
(VKTX) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views? - Yahoo Finance
Viking Therapeutics (VKTX) Starts A Phase 1 Obesity Trial, Is The Upside Already Priced In? - simplywall.st
VKTX Stock Draws Fresh Attention Ahead Of Earnings: Wall Street Sees Over 170% Upside As GLP-1 Race Burns Hot - Stocktwits
VKTX Stock Rises After-Hours: CNBC Flags Viking As Likely Buyout Target This Year As Big Pharma Hunts Next GLP-1 Winner - Stocktwits
ETFs Investing in Viking Therapeutics, Inc. Stocks - TradingView
VKTX Stock On Track For Five Consecutive Days Of Gains — Viking Launches Human Trial For Novel Obesity Drug VK3019 - Stocktwits
Enterprise value to EBITDA forward of Viking Therapeutics, Inc. – NASDAQ:VKTX - TradingView
Enterprise value to EBIT forward of Viking Therapeutics, Inc. – NASDAQ:VKTX - TradingView
A New Obesity Drug Just Reached Human Trials. Here's What Comes Next - Streetwise Reports
Price to earnings forward of Viking Therapeutics, Inc. – NASDAQ:VKTX - TradingView
Enterprise value to EBIT forward of Viking Therapeutics, Inc. – FWB:1VT - TradingView
Price to sales forward of Viking Therapeutics, Inc. – NASDAQ:VKTX - TradingView
Enterprise value to EBIT forward of Viking Therapeutics, Inc. – LS:A12GD6 - TradingView
Enterprise value to revenue forward of Viking Therapeutics, Inc. – NASDAQ:VKTX - TradingView
Price to sales forward of Viking Therapeutics, Inc. – FWB:1VT - TradingView
Price to book forward of Viking Therapeutics, Inc. – NASDAQ:VKTX - TradingView
VKTX Eyes Worst Week Since November As Trial Data Looms — Wall Street Still Sees 200% Upside - Stocktwits
VKTX Stock Price, Quote & Chart - ChartMill
Is Viking Therapeutics Poised to Disrupt the Weight-Loss Market - Kavout | AI
Dyne Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? - Yahoo Finance
1.18%
2.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):